

RESEARCH

Open Access

# Angiotensin II produces nociceptive behavior through spinal AT<sub>1</sub> receptor-mediated p38 mitogen-activated protein kinase activation in mice

Wataru Nemoto<sup>1</sup>, Osamu Nakagawasai<sup>1</sup>, Fukie Yaoita<sup>1</sup>, Syu-Ichi Kanno<sup>2</sup>, Shin Yomogida<sup>2</sup>, Masaaki Ishikawa<sup>2</sup>, Takeshi Tadano<sup>3</sup> and Koichi Tan-No<sup>1\*</sup>

## Abstract

**Background:** It has been demonstrated that angiotensin II (Ang II) participates in either the inhibition or the facilitation of nociceptive transmission depending on the brain area. Neuronal Ang II is locally synthesized not only in the brain, but also in the spinal cord. Though the spinal cord is an important area for the modulation of nociception, the role of spinal Ang II in nociceptive transmission remains unclear. Therefore, in order to elucidate the role of Ang II in nociceptive transmission in the spinal cord, we examined the effect of intrathecal (i.t.) administration of Ang II into mice.

**Results:** I.t. administration of Ang II produced a behavioral response in mice mainly consisting of biting and/or licking of the hindpaw and the tail along with slight hindlimb scratching directed toward the flank. The behavior induced by Ang II (3 pmol) was dose-dependently inhibited by intraperitoneal injection of morphine (0.1-0.3 mg/kg), suggesting that the behavioral response is related to nociception. The nociceptive behavior was also inhibited dose-dependently by i.t. co-administration of losartan (0.3-3 nmol), an Ang II type 1 (AT<sub>1</sub>) receptor antagonist, and SB203580 (0.1-1 nmol), a p38 MAPK inhibitor. However, the Ang II type 2 (AT<sub>2</sub>) receptor antagonist PD123319, the upstream inhibitor of ERK1/2 phosphorylation U0126, and the JNK inhibitor SP600125 had no effect on Ang II-induced nociceptive behavior. Western blot analysis showed that the i.t. injection of Ang II induced phosphorylation of p38 MAPK in the lumbar dorsal spinal cord, which was inhibited by losartan, without affecting ERK1/2 and JNK. Furthermore, we found that AT<sub>1</sub> receptor expression was relatively high in the lumbar superficial dorsal horn.

**Conclusions:** Our data show that i.t. administration of Ang II induces nociceptive behavior accompanied by the activation of p38 MAPK signaling mediated through AT<sub>1</sub> receptors. This observation indicates that Ang II may act as a neurotransmitter and/or neuromodulator in the spinal transmission of nociceptive information.

## Background

Angiotensin II (Ang II), a main bioactive component of the renin-angiotensin system (RAS), plays a critical role in sympathetic regulation, cardiovascular control, fluid balance and hormone secretion (for review, see Refs [1,2]). In the RAS, renin converts angiotensinogen to angiotensin I (Ang I), which in turn is cleaved by angiotensin-converting enzyme (ACE) to Ang II. Ang II mediates its biological effects

through Ang II type 1 (AT<sub>1</sub>) receptors and Ang II type 2 (AT<sub>2</sub>) receptors, which are seven transmembrane receptors with approximately 30% amino acid sequence similarity. Most species express a single type of AT<sub>1</sub> receptors, but two related AT<sub>1A</sub> and AT<sub>1B</sub> receptor subtypes are expressed in rodents (for review, see Ref [3]). Ang II is not only generated by circulating ACE, but also produced locally in tissues. The existence of local tissue-based RAS, independent of the classical circulating RAS, has been established in several organs (for review, see Ref [4]). The tissue RAS is characterised by the presence of all RAS components, including angiotensinogen, renin, ACE, Ang I, Ang II and

\* Correspondence: koichi@tohoku-pharm.ac.jp

<sup>1</sup>Department of Pharmacology, Tohoku Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai 981-8558, Japan

Full list of author information is available at the end of the article

Ang II receptors, and is found in the heart [5], blood vessels [6], kidney [7], pancreas [8], brain [9] and adipose tissue [10]. Evidence indicates that Ang II is involved in the modulation of nociceptive transmission. Namely, Ang II causes hyperalgesia in the caudal ventrolateral medulla (CVLM) [11] and hypoalgesia in the periaqueductal gray (PAG) and the rostral ventromedial medulla (RVM) [12-14]. However, the role of spinal Ang II in the modulation of nociceptive transmission remains unclear.

Ang II acts as an activator of mitogen-activated protein kinase (MAPK) [15-17], a family of Ser/Thr kinases that convert extracellular stimuli into a wide range of cellular responses. The MAPKs include extracellular signal-regulated kinase (ERK) 1/2, c-Jun N-terminus kinase (JNK) and p38 MAPK. These MAPKs have common activation motif (T-X-Y), which are phosphorylated by MAPK kinase. It has been reported that ERK1/2 and JNK are activated in several pain models involving peripheral inflammation, noxious heat and electric stimulation, and that the corresponding nociceptive behaviors are blocked by their respective kinases inhibitor [18-21]. In addition, p38 MAPK, which is activated by cellular stress and proinflammatory cytokines, is considered as a stress-induced kinase and plays a critical role in inflammatory responses. Spinal p38 MAPK is activated by complete Freund's adjuvant (CFA)-induced peripheral inflammation and nociceptive responses accompanying the inflammation are markedly decreased by p38 MAPK inhibitor [22]. Inhibition of p38 MAPK also reduces the mRNA expression of proinflammatory cytokines such as IL-1 $\beta$ , IL-6 and TNF $\alpha$  [22]. These observations indicate that ERK1/2, JNK and p38 MAPK are involved in the facilitation of nociceptive transmission.

We have previously found that intrathecal (i.t.) administration into mice of dynorphin [23,24], spermine [25], D-cycloserine [26] and serotonin releaser [27] produces nociceptive behavior. In the present study, we found that i.t.-administered Ang II also produced nociceptive behavior. To gain insight into the mechanism of Ang II-induced

nociceptive behavior, we determined whether Ang II receptor subtypes and MAPK signaling were involved.

## Results


### Behavioral response induced by i.t.-administered Ang II

I.t.-administered Ang II (3 pmol) produced a characteristic behavioral response consisting of scratching, biting and licking, which almost disappeared 25 min after the injection (Figure 1a). Two-way repeated-measures ANOVA revealed significant effects of the treatment ( $F_{1,18} = 6.89$ ,  $p < 0.05$ ) and time ( $F_{5,90} = 2.41$ ,  $p < 0.05$ ) but not treatment  $\times$  time interaction ( $F_{5,90} = 0.89$ ,  $p = 0.17$ ). As seen in Figure 1b, a dose-dependent increase in the total time of scratching, biting and licking for 25 min was observed following i.t. administration of Ang II (1-3 pmol). One-way ANOVA revealed a significant effect of treatment ( $F_{3,36} = 3.47$ ,  $p < 0.05$ ). A post-hoc test demonstrated a significant increase in the behavioral responses induced by injection of Ang II (3 pmol) compared to the Ringer-administered group ( $p < 0.05$ ). Therefore, the latter dose of Ang II was used in subsequent injections which were followed by a 25 min observation period.


To determine whether the Ang II-induced behavior is related to nociception, we examined the effect of a pre-treatment with morphine. As shown in Figure 2, morphine (0.1-0.3 mg/kg, i.p.) inhibited the Ang II-induced behavior in a dose-dependent manner with an ID50 value of 0.19 (0.14-0.27) mg/kg, suggesting that the behavioral response is related to nociception (one-way ANOVA analysis,  $F_{4,45} = 3.34$ ,  $p < 0.05$ ; post hoc test,  $p < 0.01$  for Ringer versus Ang II,  $p < 0.05$  for Ang II versus Ang II plus 0.3 mg/kg morphine).

### Effects of Ang II receptor antagonists on Ang II-induced nociceptive behavior

To determine which type of Ang II receptors is involved in the nociceptive behavior, we compared the effects of losartan, an AT<sub>1</sub> receptor antagonist, to



**Figure 1** Scratching, biting and licking responses induced by i.t.-administered Ang II in mice. **(a)** Time course of behavioral response induced by Ang II (3 pmol) or Ringer's solution alone. The ordinate shows the total time of scratching, biting and licking that occurred during each 5 min of measurement. **(b)** Effects of varying doses of Ang II (1-3 pmol/mouse). The duration of scratching, biting and licking induced by Ang II or Ringer's solution was determined over a 25 min period starting immediately after i.t. injection. Values represent the means  $\pm$  S.E.M. for groups of 10 mice. \* $p < 0.05$  compared with Ringer controls.



PD123319, an AT<sub>2</sub> receptor antagonist. Losartan (0.3-3 nmol) co-administered i.t. with Ang II caused a dose-dependent inhibition of Ang II-induced nociceptive behavior with an ID<sub>50</sub> value of 0.55 (0.47-0.63) nmol (one-way ANOVA analysis,  $F_{4,45} = 3.45$ ,  $p < 0.05$ ; post hoc test,  $p < 0.01$  for Ringer versus Ang II,  $p < 0.05$  for Ang II versus Ang II plus 1 and 3 nmol losartan, Figure 3a). In contrast, i.t.-administered PD123319 (1 and 3 nmol) did not affect the nociceptive behavior induced by Ang II (one-way ANOVA analysis,  $F_{3,36} = 2.74$ ,  $p < 0.05$ ; post hoc test,  $p > 0.05$  for Ang II versus Ang II plus 1 and 3 nmol PD123319, Figure 3b). These results indicate i.t. Ang II-induced nociceptive behavior is mediated through AT<sub>1</sub> receptors but not through AT<sub>2</sub> receptors.

#### Distribution of AT<sub>1</sub> receptors in mouse spinal cord


The distribution of AT<sub>1</sub> receptor fluorescence intensity in mouse spinal cord (L5) was determined by microphotometry and categorized into 18 levels (shown as different colors in Figure 4b, with the lowest concentration shown as black and the highest concentration represented by white). Relatively high intensity of AT<sub>1</sub> receptor fluorescence was seen in the superficial dorsal horn (laminae I and II).


#### Effects of MEK and MAPK inhibitors on Ang II-induced nociceptive behavior

The role of ERK1/2, JNK and p38 MAPK signaling in Ang II-induced nociceptive behavior was examined using the inhibitors U0126, SP600125, and SB203580, respectively. U0126 (1 and 3 nmol) co-administered i.t. with Ang II did not affect the nociceptive behavior induced by Ang II (one-way ANOVA analysis,  $F_{3,36} = 5.11$ ,  $p < 0.01$ ; post hoc test,  $p > 0.05$  for Ang II versus Ang II plus 1 and 3 nmol U0126, Figure 5a). Similarly, SP600125 (0.3 and 3 nmol) did not affect the nociceptive behavior induced by Ang II (one-way ANOVA analysis,  $F_{3,36} = 5.82$ ,  $p < 0.01$ ; post hoc test,  $p > 0.05$  for Ang II versus Ang II plus 0.3 and 3 nmol SP600125, Figure 5b). On the other hand, i.t.-administered SB203580 (0.1-1 nmol) caused a dose-dependent inhibition of Ang II – induced nociceptive behavior with an ID<sub>50</sub> value of 0.34 (0.32-0.37) nmol (one-way ANOVA analysis,  $F_{4,45} = 4.72$ ,  $p < 0.01$ ; post hoc test,  $p < 0.05$  for Ang II versus Ang II plus 1 nmol SB203580, Figure 5c). These results suggest that p38 MAPK, but not ERK1/2 and JNK is critically involved in the nociceptive behavior produced by Ang II.

#### Phosphorylation of MAPKs in the dorsal spinal cord after i.t. injection of Ang II

To investigate whether spinal MAPKs were activated by i.t. injection of Ang II (3 pmol), we examined the phosphorylation of ERK1/2, JNK and p38 MAPK in the






**Figure 4** Distribution of the immunohistochemical fluorescence intensity for AT<sub>1</sub> receptors in mouse lumbar spinal cord (L5). (a) Diagram representing segment L5 of the spinal cord. (b) Quantitative immunohistochemical distribution of AT<sub>1</sub> receptors in the lumbar spinal cord.

lumbar dorsal cord extracted 10 min after i.t. injection by Western blotting. Ang II did not affect the phosphorylation of ERK1/2 ( $t = 0.47$ ,  $p > 0.05$ , Figure 6a) and JNK ( $t = 0.97$ ,  $p > 0.05$ , Figure 6b). As shown in Figure 6c and d, Ang II increased the phosphorylation of p38 MAPK in the lumbar dorsal cord. In addition, as seen in Figure 6c, losartan inhibited the p38 MAPK phosphorylation induced by Ang II (one-way ANOVA analysis,  $F_{2,9} = 4.50$ ,  $p < 0.05$ ; post hoc test,  $p < 0.05$  for Ang II versus Ang II plus 3 nmol losartan). In contrast, PD123319 did not affect the p38 MAPK phosphorylation induced by Ang II


(one-way ANOVA analysis,  $F_{2,9} = 6.99$ ,  $p < 0.05$ ; post hoc test,  $p > 0.05$  for Ang II versus Ang II plus 3 nmol PD123319, Figure 6d). These results indicate that i.t.-administered Ang II produces p38 MAPK phosphorylation mediated through AT<sub>1</sub> receptors but not through AT<sub>2</sub> receptors in the lumbar dorsal cord.

## Discussion

In the present study, we demonstrated for the first time that i.t.-administered Ang II in mice induced a characteristic behavioral response mainly consisting of biting



**Figure 5** Effects of MEK and MAPK inhibitors on i.t. Ang II-induced nociceptive behavior in mice. U0126 (a), SP600125 (b) and SB203580 (c) were co-administered i.t. with Ang II (3 pmol). The duration of scratching, biting and licking induced by Ang II was determined over a 25 min period starting immediately after i.t. injection. Values represent the means  $\pm$  S.E.M. for groups of 10 mice. \*\* $p < 0.01$  compared with vehicle (6.8% DMSO) controls and # $p < 0.05$  compared with Ang II alone. n.s., not significant.



**Figure 6 Alterations in spinal MAPKs phosphorylation by Ang II and the effects of losartan and PD123319.** Dorsal spinal cord samples were taken 10 min after i.t. injection of Ang II (3 pmol). Phosphorylation of ERK1/2 (**a**), JNK (**b**) and p38 MAPK (**c**, **d**) were examined by Western blotting. Losartan (3 nmol) or PD123319 (3 nmol) was co-administered i.t. with Ang II. Top: representative Western blot of total- and phospho-MAPKs. Bottom: quantification of phospho-MAPKs to total-MAPKs set as 1.0 in the Ringer- or vehicle (6.8% DMSO)-treated group. Each value represents the means  $\pm$  S.E.M. of 4 mice in each group. \* $p < 0.05$  compared with Ringer or vehicle controls and # $p < 0.05$  compared with Ang II alone. n.s., not significant.

and/or licking of the hindpaw and the tail along with slight hindlimb scratching directed toward the flank, indicative of nociceptive responses, accompanied by the activation of p38 MAPK mediated through  $AT_1$  receptors.

Ang II was originally discovered as a potent vasoconstrictor, while recent studies have shown that Ang II affects a wide range of central and peripheral components of sensory systems [13,28,29]. It has been demonstrated that the administration of Ang II either i.c.v. or directly in key components of the supraspinal pain modulatory system, namely the PAG or RVM (for review, see Ref [30]), induces antinociceptive effects, which are reversed by losartan [12,13,31,32]. On the other hand,

Marques-Lopes et al. [11] have recently reported that the microinjection of Ang II into the CVLM induces hyperalgesia through  $AT_1$  receptors, and that the effect of Ang II on spinal nociceptive processing is likely indirect, since few  $AT_1$  receptor-expressing CVLM neurons were found to project to the spinal cord. These reports lead us to suggest that supraspinal Ang II may participate in both inhibition and facilitation of the nociceptive transmission and its effect is region-dependent. However, the role of Ang II in the modulation of nociceptive transmission in the spinal cord has not been reported until this study. Therefore, it is important to clarify the role of spinal Ang II in the modulation of nociception.



Recently, it has been reported that Ang II is colocalized with calcitonin gene-related peptide (CGRP) and substance P, the neuropeptides established as the key regulators of sensory transmission and nociception, in rat and human dorsal root ganglia (DRG) [33]. Takai et al. [34] have revealed that repeated oral administration of AT<sub>1</sub> receptor antagonist and ACE inhibitors show antinociceptive effect in hot-plate test. Furthermore, we have found that i.t.-administered losartan produces antinociceptive effect in a mouse formalin test (data not shown). These findings suggest that Ang II may act as a neurotransmitter and/or neuromodulator in the transmission of nociceptive information in the spinal cord. In the present study, we found that i.t.-administered Ang II (3 pmol) produced a nociceptive behavior consisting of scratching, biting and licking. We also observed that the Ang II-induced nociceptive behavior was inhibited by losartan but not by PD123319, indicating that receptor type 1 and not type 2 for Ang II is involved. Regarding the distribution of spinal AT<sub>1</sub> receptors, Pavel et al. [35] have reported that the receptors are present in high density in the lumbar superficial dorsal horn (laminae I and II) using autoradiography in rat. In this study, we also detected a relatively high intensity of fluorescence for AT<sub>1</sub> receptors in the mouse lumbar superficial dorsal horn. Our results obtained with behavioral and immunohistochemical experiments suggest that spinal AT<sub>1</sub> receptors are responsible for the nociceptive response.

Ang II induced two peaks of nociceptive behavior, one at 5–10 and the other 20–25 min after injection, although there was no significant difference between time × treatment interaction. The hydrolysis of Ang II by a homogenate of rat ventrolateral PAG forms Ang III, a major hydrolysis product, Ang IV, Ang (1–7) and Ang (1–4) [36]. Moreover, microinjection of Ang III into the ventrolateral PAG produces the antinociceptive effect mediated through AT<sub>1</sub> and AT<sub>2</sub> receptors [36]. Therefore, we may speculate that in our time course experiment, Ang II is responsible for the first peak while Ang III generated from Ang II is responsible for the second peak.

ERK1/2, JNK and p38 MAPK are phosphorylated in the presence of Ang II in mouse atrial fibroblasts [15] and natural killer cells [16], while only ERK1/2 and p38 MAPK but not JNK are phosphorylated by Ang II in RVM [17]. In addition, Sung et al. [37] have reported that i.t.-administered IL-1 $\beta$  activates only p38 MAPK without affecting ERK1/2 and JNK in the spinal cord. Similarly, in this study, only the spinal p38 MAPK was activated after i.t. administration of Ang II, although the ERK1/2, JNK and p38 MAPK were constitutively expressed in the spinal cord. There are four p38 MAPK isoforms: p38 $\alpha$ , p38 $\beta$ , p38 $\gamma$  and p38 $\delta$ . Whereas p38 $\alpha$  and p38 $\beta$  are two of the major isoforms in the mature nervous system, p38 $\alpha$  is the most abundant isoform in DRG neuron and spinal

cord (for review, see [38]). Therefore, we used SB203580 to inhibit p38 MAPK signaling in the spinal cord since it can inhibit the activity of both p38 $\alpha$  and p38 $\beta$  isoforms [39]. In this study, the behavioral observation revealed that Ang II-induced nociceptive response was almost completely inhibited by SB203580. On the other hand, neither U0126 nor SP600125 affected the Ang II-induced nociceptive behavior. Ample evidence suggest that the spinal p38 MAPK is involved in several types of pain. Phosphorylation of spinal p38 MAPK has been observed not only in neuropathic pain models such as chronic constriction injury [40,41] and spinal nerve ligation [42–44], but also in peripheral inflammation induced by CFA [22], bee-venom [45], formalin [46–48] and capsaicin [48]. Moreover, i.t. administration of *N*-methyl-D-aspartate (NMDA) produces thermal hyperalgesia through spinal p38 MAPK phosphorylation [49]. Taken together with these previous reports, our present results indicate that the phosphorylation of spinal p38 MAPK, but not of the other MAPKs, is involved in Ang II-induced nociceptive behavior. In addition, since the nociceptive behavior arises rapidly and declines within 25 min to resemble controls, we suggest that the phosphorylation of p38 MAPK leads to the behavior via non-transcriptional mechanisms. Mizushima et al. [50] have reported that intraplantar injection into rats of capsaicin induces phosphorylation of p38 MAPK in DRG neurons and thermal hyperalgesia which peak at 2–5 min after injection. Although the specific target proteins of p38 MAPK are not clearly identified, p38 MAPK signaling pathway leads to Ang II-induced nociceptive behavior through post-transcriptional modifications of kinases, receptors and ion-channels.

Finally, we examined the effects of Ang II receptor antagonists on p38 MAPK phosphorylation in the dorsal spinal cord. Whereas p38 MAPK phosphorylation was inhibited by losartan, it was resistant against PD123319, and these results were consistent with those of the behavioral experiments. It has been reported that Ang II increases the phosphorylation of p38 MAPK in cultured rat neonatal cardiomyocytes, which is attenuated by losartan similarly to SB205380, a p38 MAPK inhibitor, and p38 siRNA [51]. Taken together, the present results suggest that phosphorylation of p38 MAPK mediated through AT<sub>1</sub> but not AT<sub>2</sub> receptors contributes to i.t. Ang II-induced nociceptive behavior.

## Conclusions

In conclusion, our data show that i.t.-administered Ang II induces nociceptive behavior accompanied by p38 MAPK phosphorylation mediated through spinal AT<sub>1</sub> receptors. Moreover, it is suggested that Ang II may be a neurotransmitter and/or neuromodulator in the transmission of nociceptive information in the spinal cord.

## Methods

### Animals

Male ddY strain mice (weighing 22–24 g, Japan SLC, Japan) were used in all experiments. Mice were housed in cages with free access to food and water under conditions of constant temperature ( $22 \pm 2^\circ\text{C}$ ) and humidity ( $55 \pm 5\%$ ), on a 12 h light–dark cycle (lights on: 08:00 to 20:00). Groups of 10 mice for behavioral experiments and 4 mice for Western blotting and immunohistochemical experiments were used in single experiments. All experiments were performed following the approval from the Ethics Committee of Animal Experiment in Tohoku Pharmaceutical University and according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Efforts were made to minimize suffering and to reduce the number of animals used.

### Intrathecal injections

The i.t. injections were made in unanaesthetized mice at the L5, L6 intervertebral space as described by Hyden and Wilcox [52]. Briefly, a volume of 5  $\mu\text{l}$  was administered i.t. with a 28-gauge needle connected to a 50- $\mu\text{l}$  Hamilton microsyringe, the animal being lightly restrained to maintain the position of the needle. Puncture of the dura was indicated behaviorally by a slight flick of the tail.

### Behavioral observation

Approximately 60 min before the i.t. injection, the mice were habituated to an individual cage ( $22.0 \times 15.0 \times 12.5$  cm) which was also used as the observation chamber after injection. Immediately after the i.t. injection, the mice were placed in the transparent cage and the accumulated response time of hindlimb scratching directed toward the flank, biting and/or licking of the hindpaw and the tail was measured for 25 min with the exception of the 30 min time course experiment in which the response was divided into 5 min intervals.

### Drugs and antibodies

The following drugs and chemicals were used: Ang II (Peptide Institute, Japan); morphine hydrochloride (Sankyo, Japan); losartan potassium (LKT Laboratories, USA); 1-[[4-(dimethylamino)-3-methylphenyl]methyl]-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1*H*-imidazo[4,5-*c*]pyridine-6-carboxylic acid ditrifluoroacetate (PD123319), 1,4-diamino-2,3-dicyano-1,4-*bis*[2-aminophenylthio]butadiene (U0126), 4-[5-(4-fluorophenyl)-2-[4-(methylsulphonyl)phenyl]-1*H*-imidazol-4-yl]pyridine hydrochloride (SB203580 hydrochloride) (Tocris Bioscience, USA); anthra (1,9-*cd*) pyrazol-6(2*H*)-one, 1,9-pyrazoloanthrone (SP600125) (Alexis, USA); sodium pentobarbital (Dainippon Sumitomo Pharma, Japan); antibodies against ERK1/2, phospho-ERK1/2, JNK, phospho-JNK, p38 MAPK, phospho-p38 MAPK, and horseradish peroxidase

(HRP)-conjugated goat anti-rabbit IgG antibody (Cell Signaling Technology, USA); anti-AT<sub>1</sub> receptor antibody (Alpha Diagnostic, USA); enhanced chemiluminescence (ECL) assay kit (GE Healthcare, England). For i.t. injections, Ang II and losartan were dissolved in Ringer's solution. PD123319, U0126, SB203580 and SP600125 were dissolved in Ringer's solution containing 6.8% dimethyl sulfoxide (DMSO). When the effects of Ang II receptor antagonists and MAPK-related inhibitors were tested, they were co-injected with Ang II in a volume of 5  $\mu\text{l}$ . Morphine was dissolved in physiological saline and administered intraperitoneally (i.p.) 5 min prior to injection of Ang II.

### Immunohistochemical staining

Spinal cords for measurement of AT<sub>1</sub> receptors were prepared within 24 h following delivery. Mice were anesthetized with sodium pentobarbital (50 mg/kg, i.p.) and perfused through the heart with ice-cold phosphate-buffered saline (PBS, pH 7.2), immediately followed by a fixative containing 4% paraformaldehyde (Sigma–Aldrich, USA) and 0.2% glutaraldehyde (Nacalai Tesque, Japan) in PBS. Spinal cords (lumbar 5; L5) were then postfixed with the same fixative solution at  $4^\circ\text{C}$  for 1 h and then placed in a 20% sucrose-buffered solution at  $4^\circ\text{C}$  for 12 h. Tissues were frozen on dry ice and cut into 20  $\mu\text{m}$ -thick coronal sections on a cryostat (Micro-edge Instruments Co. Ltd., Germany). The immunohistochemical staining procedure was carried out as previously described [53]. Briefly, a rabbit anti-AT<sub>1</sub> receptor antibody (diluted 1:100 with PBS and 5% normal goat serum (NGS); Millipore Co., USA) was applied to spinal cord slices, which were then incubated at  $4^\circ\text{C}$  for 12 h. The secondary antibody consisted of FITC-labeled anti-rabbit IgG goat serum (diluted 1:200 with PBS; Millipore Co.), and was allowed to react in the dark at room temperature for 2 h. The stained sections were mounted in Dako Fluorescence Mounting Medium (Dako North America, USA), and kept at  $4^\circ\text{C}$  in a dark room until measurements were carried out. The distribution of AT<sub>1</sub> receptor immunofluorescence intensities was quantitatively analyzed using a MapAnalyzer (Yamato Scientific Co., Japan). The background value, including non-specific fluorescence originating from glutaraldehyde, was subtracted photometrically from the total fluorescence intensity value at each point measured.

### SDS-polyacrylamide gel electrophoresis and immunoblotting

Samples used for immunoblotting were prepared as follows. At 10 min after i.t. injection, mice were decapitated and the whole spinal cord was taken by pressure expulsion with physiological saline. The dorsal part of lumbar spinal cord was dissected quickly on ice-cooled glass dish. The tissue samples were homogenized in

0.15 ml of CellLytic™ MT Mammalian Tissue Lysis/Extraction Reagent (Sigma Aldrich, USA) and centrifuged the lysis sample at 15,000×g for 15 min at 4°C. Supernatants were dissolved in 4 × Laemmli sample buffer (300 mM Tris-HCl pH 6.8, 8% SDS, 40% glycerol, 12% 2-mercaptoethanol and 0.012% bromophenol blue), and boiled at 95°C for 10 min. Electrophoresis was performed on 10% acrylamide gels. Proteins were transferred electrically from the gel onto a polyvinylidene difluoride membrane (Bio-Rad Laboratories, Japan) by the semi-dry blotting method. The blots were blocked for 30 min with 5% skim-milk in Tris-buffered saline supplemented with 0.1% Tween-20, and incubated with primary antibodies overnight at 4°C. The blots were washed several times and then incubated at room temperature for 2 h with a secondary antibody (HRP-conjugated anti-rabbit IgG antibody). Blots were developed using an enhanced chemiluminescence assay kit, and visualized by chemiluminescence on Hyper-film ECL. The densities of the bands were analyzed by densitometry (Image-J 1.43u, National Institute of Health).

#### Statistical methods

Data were expressed as mean ± SEM. The ID<sub>50</sub> values with 95% confidence limits were calculated for reduction in Ang II-induced scratching, biting and licking response by a computer-associated curve-fitting program (GraphPad Prism; GraphPad Software, USA). The significant differences were analyzed by a one-way or two-way analysis of variance (ANOVA), followed by Fisher's PLSD test for multiple-comparisons. Student's *t* test was used for comparisons between two groups. In all comparisons, *P* < 0.05 was considered statistical significance.

#### Abbreviations

ACE: angiotensin-converting enzyme; Ang: Angiotensin; AT<sub>1</sub>: Ang II type 1; AT<sub>2</sub>: Ang II type 2; CFA: complete Freund's adjuvant; CGRP: calcitonin gene-related peptide; CVM: caudal ventrolateral medulla; DMSO: dimethyl sulfoxide; DRG: dorsal root ganglia; ERK: extracellular signal-regulated kinase; ID<sub>50</sub>: inhibitory dose 50%; i.p.: intraperitoneal; i.t.: intrathecal; JNK: c-Jun N-terminus kinase; MAPK: mitogen-activated protein kinase; NMDA: N-methyl-D-aspartate; PAG: periaqueductal gray; RAS: renin-angiotensin system; RVM: rostral ventromedial medulla.

#### Competing interests

The authors declare that they have no competing interests.

#### Authors' contributions

WN designed, performed the experiments and wrote the manuscript. ON performed immunohistochemical experiment and analyzed the data. FY, SK and SY contributed to design of experimentation. MI and TT supervised the experiments. KT supervised the experiments, and participated in their design and coordination, and helped to draft the manuscript. All authors read and approved the final manuscript.

#### Acknowledgements

This study was supported in part by JSPS KAKENHI Grant Number 21600012 to KT, JSPS KAKENHI Grant Number 22600010 to ON, and Matching Fund Subsidy for Private University from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

#### Author details

<sup>1</sup>Department of Pharmacology, Tohoku Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai 981-8558, Japan. <sup>2</sup>Department of Clinical Pharmacotherapeutics, Tohoku Pharmaceutical University, Aoba-ku, Sendai 981-8558, Japan. <sup>3</sup>Laboratory of Environmental and Health Sciences, College of Medical Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa 920-1192, Japan.

Received: 9 April 2013 Accepted: 24 July 2013

Published: 31 July 2013

#### References

1. Paul M, Poyan Mehr A, Kreutz R: Physiology of local renin-angiotensin systems. *Physiol Rev* 2006, **86**:747.
2. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T: International union of pharmacology. XXIII. The angiotensin II receptors. *Pharmacol Rev* 2000, **52**:415–472.
3. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JA, Smith RD: Angiotensin II receptors and angiotensin II receptor antagonists. *Pharmacol Rev* 1993, **45**:205–251.
4. Bader M: Tissue renin-angiotensin-aldosterone systems: Targets for pharmacological therapy. *Annu Rev Pharmacol Toxicol* 2010, **50**:439–465.
5. Villarreal FJ, Kim NN, Ungab GD, Printz MP, Dillmann WH: Identification of functional angiotensin II receptors on rat cardiac fibroblasts. *Circulation* 1993, **88**:2849–2861.
6. Nguyen Dinh Cat A, Touyz RM: A new look at the renin-angiotensin system—focusing on the vascular system. *Peptides* 2011, **32**:2141–2150.
7. Zhuo JL, Li XC: New insights and perspectives on intrarenal renin-angiotensin system: focus on intracrine/intracellular angiotensin II. *Peptides* 2011, **32**:1551–1565.
8. Leung PS: Pancreatic RAS. *Adv Exp Med Biol* 2010, **690**:89–105.
9. Wright JW, Harding JW: Brain renin-angiotensin—a new look at an old system. *Prog Neurobiol* 2011, **95**:49–67.
10. Thatcher S, Yiannikouris F, Gupte M, Cassis L: The adipose renin-angiotensin system: role in cardiovascular disease. *Mol Cell Endocrinol* 2009, **302**:111–117.
11. Marques-Lopes J, Pinto M, Pinho D, Morato M, Patinha D, Albino-Teixeira A, Tavares I: Microinjection of angiotensin II in the caudal ventrolateral medulla induces hyperalgesia. *Neuroscience* 2009, **158**:1301–1310.
12. Prado WA, Pelegrini-da-Silva A, Martins AR: Microinjection of renin-angiotensin system peptides in discrete sites within the rat periaqueductal gray matter elicits antinociception. *Brain Res* 2003, **972**:207–215.
13. Pelegrini-da-Silva A, Martins AR, Prado WA: A new role for the renin-angiotensin system in the rat periaqueductal gray matter: angiotensin receptor-mediated modulation of nociception. *Neuroscience* 2005, **132**:453–463.
14. Yien HW, Chan JY, Tsai HF, Lee TY, Chan SH: Participation of nucleus reticularis gigantocellularis in the antinociceptive effect of angiotensin III in the rat. *Neurosci Lett* 1993, **159**:9–12.
15. Gu J, Liu X, Wang QX, Tan HW, Guo M, Jiang WF, Zhou L: Angiotensin II increases CTGF expression via MAPKs/TGF-beta1/TRAF6 pathway in atrial fibroblasts. *Exp Cell Res* 2012, **318**:2105–2115.
16. Yang L, Du C, Chen T, Li S, Nie W, Zhu W, Fan F, Zhu J, Yan H: Distinct MAPK pathways are involved in IL-23 production in dendritic cells cocultured with NK cells in the absence or presence of angiotensin II. *Mol Immunol* 2012, **51**:51–56.
17. Chan SH, Hsu KS, Huang CC, Wang LL, Ou CC, Chan JY: NADPH oxidase-derived superoxide anion mediates angiotensin II-induced pressor effect via activation of p38 mitogen-activated protein kinase in the rostral ventrolateral medulla. *Circ Res* 2005, **97**:772–780.
18. Ji RR, Baba H, Brenner GJ, Woolf CJ: Nociceptive-specific activation of ERK in spinal neurons contributes to pain hypersensitivity. *Nat Neurosci* 1999, **2**:1114–1119.
19. Dai Y, Iwata K, Fukuoka T, Kondo E, Tokunaga A, Yamanaka H, Tachibana T, Liu Y, Noguchi K: Phosphorylation of extracellular signal-regulated kinase in primary afferent neurons by noxious stimuli and its involvement in peripheral sensitization. *J Neurosci* 2002, **22**:7737–7745.
20. Ma W, Quirion R: Partial sciatic nerve ligation induces increase in the phosphorylation of extracellular signal-regulated kinase (ERK) and c-Jun



- N-terminal kinase (JNK) in astrocytes in the lumbar spinal dorsal horn and the gracile nucleus. *Pain* 2002, **99**:175–184.
21. Galan A, Cervero F, Laird JM: Extracellular signaling-regulated kinase-1 and -2 (ERK 1/2) mediate referred hyperalgesia in a murine model of visceral pain. *Brain Res Mol Brain Res* 2003, **116**:126–134.
  22. Boyle DL, Jones TL, Hammaker D, Svensson CI, Rosengren S, Albani S, Sorkin L, Firestein GS: Regulation of peripheral inflammation by spinal p38 MAP kinase in rats. *PLoS Med* 2006, **3**:e338.
  23. Tan-No K, Esashi A, Nakagawasai O, Nijijima F, Tadano T, Sakurada C, Sakurada T, Bakalkin G, Terenius L, Kisara K: Intrathecally administered big dynorphin, a prodynorphin-derived peptide, produces nociceptive behavior through an N-methyl-D-aspartate receptor mechanism. *Brain Res* 2002, **952**:7–14.
  24. Tan-No K, Takahashi H, Nakagawasai O, Nijijima F, Sato T, Satoh S, Sakurada S, Marinova Z, Yakovleva T, Bakalkin G, et al: Pronociceptive role of dynorphins in uninjured animals: N-ethylmaleimide-induced nociceptive behavior mediated through inhibition of dynorphin degradation. *Pain* 2005, **113**:301–309.
  25. Tan-No K, Taira A, Wako K, Nijijima F, Nakagawasai O, Tadano T, Sakurada C, Sakurada T, Kisara K: Intrathecally administered spermine produces the scratching, biting and licking behaviour in mice. *Pain* 2000, **86**:55–61.
  26. Tan-No K, Esashi A, Nakagawasai O, Nijijima F, Furuta S, Sato T, Satoh S, Yasuhara H, Tadano T: Intrathecally administered D-cycloserine produces nociceptive behavior through the activation of N-methyl-D-aspartate receptor ion-channel complex acting on the glycine recognition site. *J Pharmacol Sci* 2007, **104**:39–45.
  27. Tan-No K, Takahashi K, Shimoda M, Sugawara M, Nakagawasai O, Nijijima F, Sato T, Satoh S, Tadano T: S-(+)-fenfluramine-induced nociceptive behavior in mice: Involvement of interactions between spinal serotonin and substance P systems. *Neuropeptides* 2007, **41**:33–38.
  28. Burkhalter J, Felix D, Imboden H: A new angiotensinergic system in the CNS of the rat. *Regul Pept* 2001, **99**:93–101.
  29. Wu W, Zhang Y, Ballew JR, Fink G, Wang DH: Development of hypertension induced by suppressor infusion of angiotensin II: role of sensory nerves. *Hypertension* 2000, **36**:549–552.
  30. Gebhart GF: Descending modulation of pain. *Neurosci Biobehav Rev* 2004, **27**:729–737.
  31. Georgieva D, Georgiev V: The role of angiotensin II and of its receptor subtypes in the acetic acid-induced abdominal constriction test. *Pharmacol Biochem Behav* 1999, **62**:229–232.
  32. Raghavendra V, Chopra K, Kulkarni SK: Brain renin angiotensin system (RAS) in stress-induced analgesia and impaired retention. *Peptides* 1999, **20**:335–342.
  33. Patil J, Schwab A, Nussberger J, Schaffner T, Saavedra JM, Imboden H: Intraneuronal angiotensinergic system in rat and human dorsal root ganglia. *Regul Pept* 2010, **162**:90–98.
  34. Takai S, Song K, Tanaka T, Okunishi H, Miyazaki M: Antinociceptive effects of angiotensin-converting enzyme inhibitors and an angiotensin II receptor antagonist in mice. *Life Sci* 1996, **59**:PL331–PL336.
  35. Pavel J, Tang H, Brimijoin S, Moughamian A, Nishioku T, Benicky J, Saavedra JM: Expression and transport of Angiotensin II AT1 receptors in spinal cord, dorsal root ganglia and sciatic nerve of the rat. *Brain Res* 2008, **1246**:111–122.
  36. Pelegrini-da-Silva A, Rosa E, Guethe LM, Juliano MA, Prado WA, Martins AR: Angiotensin III modulates the nociceptive control mediated by the periaqueductal gray matter. *Neuroscience* 2009, **164**:1263–1273.
  37. Sung CS, Wen ZH, Chang WK, Chan KH, Ho ST, Tsai SK, Chang YC, Wong CS: Inhibition of p38 mitogen-activated protein kinase attenuates interleukin-1beta-induced thermal hyperalgesia and inducible nitric oxide synthase expression in the spinal cord. *J Neurochem* 2005, **94**:742–752.
  38. Ji RR, Gereau RW, Malcangio M, Strichartz GR: MAP kinase and pain. *Brain Res Rev* 2009, **60**:135–148.
  39. Enslin H, Raingeaud J, Davis RJ: Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6. *J Biol Chem* 1998, **273**:1741–1748.
  40. Gu YW, Su DS, Tian J, Wang XR: Attenuating phosphorylation of p38 MAPK in the activated microglia: a new mechanism for intrathecal lidocaine reversing tactile allodynia following chronic constriction injury in rats. *Neurosci Lett* 2008, **431**:129–134.
  41. Xu L, Huang Y, Yu X, Yue J, Yang N, Zuo P: The influence of p38 mitogen-activated protein kinase inhibitor on synthesis of inflammatory cytokine tumor necrosis factor alpha in spinal cord of rats with chronic constriction injury. *Anesth Analg* 2007, **105**:1838–1844.
  42. Jin SX, Zhuang ZY, Woolf CJ, Ji RR: p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. *J Neurosci* 2003, **23**:4017–4022.
  43. Terayama R, Omura S, Fujisawa N, Yamaai T, Ichikawa H, Sugimoto T: Activation of microglia and p38 mitogen-activated protein kinase in the dorsal column nucleus contributes to tactile allodynia following peripheral nerve injury. *Neuroscience* 2008, **153**:1245–1255.
  44. Tsuda M, Mizokoshi A, Shigemoto-Mogami Y, Koizumi S, Inoue K: Activation of p38 mitogen-activated protein kinase in spinal hyperactive microglia contributes to pain hypersensitivity following peripheral nerve injury. *Glia* 2004, **45**:89–95.
  45. Cui XY, Dai Y, Wang SL, Yamanaka H, Kobayashi K, Obata K, Chen J, Noguchi K: Differential activation of p38 and extracellular signal-regulated kinase in spinal cord in a model of bee venom-induced inflammation and hyperalgesia. *Mol Pain* 2008, **4**:17.
  46. Kim SY, Bae JC, Kim JY, Lee HL, Lee KM, Kim DS, Cho HJ: Activation of p38 MAP kinase in the rat dorsal root ganglia and spinal cord following peripheral inflammation and nerve injury. *Neuroreport* 2002, **13**:2483–2486.
  47. Svensson CI, Marsala M, Westerlund A, Calcutt NA, Campana WM, Freshwater JD, Catalano R, Feng Y, Protter AA, Scott B, Yaksh TL: Activation of p38 mitogen-activated protein kinase in spinal microglia is a critical link in inflammation-induced spinal pain processing. *J Neurochem* 2003, **86**:1534–1544.
  48. Sweitzer SM, Peters MC, Ma JY, Kerr I, Mangadu R, Chakravarty S, Dugar S, Medicherla S, Protter AA, Yeomans DC: Peripheral and central p38 MAPK mediates capsaicin-induced hyperalgesia. *Pain* 2004, **111**:278–285.
  49. Svensson CI, Hua XY, Protter AA, Powell HC, Yaksh TL: Spinal p38 MAP kinase is necessary for NMDA-induced spinal PGE(2) release and thermal hyperalgesia. *Neuroreport* 2003, **14**:1153–1157.
  50. Mizushima T, Obata K, Yamanaka H, Dai Y, Fukuoka T, Tokunaga A, Mashimo T, Noguchi K: Activation of p38 MAPK in primary afferent neurons by noxious stimulation and its involvement in the development of thermal hyperalgesia. *Pain* 2005, **113**:51–60.
  51. Wang BW, Chang H, Kuan P, Shyu KG: Angiotensin II activates myostatin expression in cultured rat neonatal cardiomyocytes via p38 MAP kinase and myocyte enhance factor 2 pathway. *J Endocrinol* 2008, **197**:85–93.
  52. Hylden JL, Wilcox GL: Intrathecal morphine in mice: a new technique. *Eur J Pharmacol* 1980, **67**:313–316.
  53. Nakagawasai O, Hozumi S, Tan-No K, Nijijima F, Arai Y, Yasuhara H, Tadano T: Immunohistochemical fluorescence intensity reduction of brain somatostatin in the impairment of learning and memory-related behaviour induced by olfactory bulbectomy. *Behav Brain Res* 2003, **142**:63–67.

doi:10.1186/1744-8069-9-38

Cite this article as: Nemoto et al.: Angiotensin II produces nociceptive behavior through spinal AT1 receptor-mediated p38 mitogen-activated protein kinase activation in mice. *Molecular Pain* 2013 **9**:38.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit

